U.S. Markets open in 2 hrs 9 mins

FibroGen (FGEN) Soars: Stock Adds 9.6% in Session

Zacks Equity Research

FibroGen, Inc. FGEN was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $37.01 to $40.71 in the past one-month time frame.

The upmove came after the company announced positive pooled roxadustat safety and efficacy results for the treatment of anemia in chronic kidney disease (CKD).

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

FibroGen currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.

FibroGen, Inc Price

FibroGen, Inc Price

FibroGen, Inc price | FibroGen, Inc Quote

Investors interested in the Medical – Drugs industry may consider Ironwood Pharmaceuticals, Inc. IRWD, which also has a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Is FGEN going up? Or down? Predict to see what others think:Up or Down

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report
 
FibroGen, Inc (FGEN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research